Sapitinib (AZD8931)

目录号：S2192 Purity: 99.96%

Sapitinib (AZD8931)是一种可逆的，ATP竞争性EGFR，ErbB2和ErbB3抑制剂，无细胞试验中IC50分别为4 nM，3 nM和4 nM，作用于NSCLC细胞更有效，作用于ErbB家族比作用于MNK1和Flt选择性强100倍。Phase 2。

Sapitinib (AZD8931) Chemical Structure

CAS: 848942-61-0

规格	价格	库存
10mM (1mL in DMSO)	2608.15	现货
5mg	1414.82	现货
10mg	2624.23	现货
50mg	7933.77	现货
1g	24488.1	现货
更大包装有超大折扣
400-668-6834 info@selleck.cn

产品质控

批次：纯度： 99.96%

99.96

Sapitinib (AZD8931)相关产品

相关产品	CP-724714 Mubritinib (TAK 165) AC480 (BMS-599626) Tyrphostin AG 879 HER2-Inhibitor-1 TAS0728	点击展开
相关化合物库	激酶抑制剂库酪氨酸激酶抑制剂分子库 PI3K/Akt 抑制剂库细胞周期化合物库血管生成相关化合物库	点击展开

细胞实验数据示例

细胞系	实验类型	孵育时间	活性描述	文献信息
MCF-7	Function assay	4 hrs	Inhibition of full-length HER2 phosphorylation transfected in in human MCF-7 cl.24 cells after 4 hrs by laser scanning fluorescence microplate cytometry, IC50 = 0.06 μM.	24900741
KB	Function assay		Inhibition of EGF-stimulated EGFR phosphorylation in human KB cells, IC50 = 0.004 μM.	24900741
MCF7	Function assay		Inhibition of heregulin-stimulated HER3 phosphorylation in human MCF7 cells, IC50 = 0.004 μM.	24900741
MCF7	Function assay		Inhibition of heregulin-stimulated HER2 phosphorylation in human MCF7 cells, IC50 = 0.003 μM.	24900741
TC32	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	29435139
DAOY	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	29435139
SJ-GBM2	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	29435139
SK-N-MC	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
BT-37	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	29435139
NB-EBc1	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	29435139
Saos-2	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	29435139
SK-N-SH	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	29435139
LAN-5	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	29435139
BT-12	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	29435139
OHS-50	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
RD	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	29435139
Rh41	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	29435139
NB1643	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	29435139
SK-N-MC	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	29435139
LAN-5	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	29435139
NB-EBc1	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	29435139
BT-37	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	29435139
TC32	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	29435139
Rh18	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	29435139
Rh30	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	29435139
点击查看更多细胞系数据

生物活性

产品描述

靶点

ErbB2 ^[1] (Cell-free assay)	EGFR ^[1] (Cell-free assay)	ErbB3 ^[1] (Cell-free assay)
3 nM	4 nM	4 nM

体外研究(In Vitro)
体外研究活性	AZD8931作用于NSCLC和SCCHN 细胞系的效果不同。AZD8931高度选择性作用于 PC-9细胞(EGFR 激活突变型),GI50为0.1 nM，而低活性作用于 NCI-1437细胞，GI50 >10 μM。AZD8931作用于 PE/CA-PJ41, PE/CA-PJ49, DOK 和FaDu细胞，更有效作用于p-EGFR, p-erbB2 和 p-erbB3。^[1]
激酶实验	分离的激酶实验
激酶实验	人类EGFR和erbB2 细胞内激酶域在杆状病毒/Sf21 系统中克隆和表达。使用ATP在 K_m浓度(0.4 mM 测定 erbB2,2 mM 测定 EGFR)，使用 ELISA 法测定AZD8931的一种活性。
细胞实验	细胞系	头颈部肿瘤细胞系(KYSE-30, OE21, PE/CA-PJ15, PE/CA-PJ34 (克隆 C12), PE/CA-PJ41 (克隆 D2), PE/CA-PJ49, DOK, Detroit562, RPMI2650, SCC-4, SCC-9, SCC-25, CAL 27, SW579, FaDu, Hs 840.T, KB, KYSE-450, 和 HEp-2, HN5) 和 NSCLC 细胞系 (PC-9, Calu-3, NCI-H2073, NCI-H1623, NCI-H522,
	浓度	0.001-10 μM
	孵育时间	96 小时
	方法	为了测定AZD8931体外抗细胞增殖活性，使用AZD8931处理一组 NSCLC 和SCCHN 细胞系。细胞和 AZD8931 (0.001-10 μM)温育96小时。细胞和 MTS 比色分析实验试剂温育4小时而测定存活细胞数，然后通过分光光度计在490 nm处测量吸光值。
实验图片	检测方法	检测指标	实验图片	PMID
	Western blot	pEGFR / EGFR / pAKT / AKT / pERK / ERK HER3 / p-HER3 / HER2 / p-HER2 / p-PRAS40 / p-S6 / p-4EBP1 / p-FOXO / PARP / cleaved PARP		27102572
	Growth inhibition assay	Cell viability		28638122

体内研究(In Vivo)
体内研究活性	AZD8931 作用于BT474c, Calu-3, LoVo, FaDu 和 PC-9移植瘤，具有抗肿瘤活性。AZD8931急性处理BT474c移植瘤，可降低 p-AKT, Ki67 表达和p-ERK。AZD8931 可诱导产生M30凋亡标记。而且, AZD8931治疗LoVo移植瘤，具有更有效的促凋亡效果。^[1]
动物实验	Animal Models	携带BT474c, Calu-3, LoVo, FaDu 和 PC-9移植瘤的Swiss 裸鼠或SCID小鼠
	Dosages	6.25-50 mg/kg
	Administration	口服饲喂

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
临床试验信息 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT01596530	Terminated	Breast Neoplasm	AstraZeneca	June 2012	Phase 1
NCT01579578	Terminated	Metastatic Gastric or Gastro-oesophageal Junction Cancer	AstraZeneca	April 2012	Phase 2
NCT01330758	Completed	Healthy	AstraZeneca	April 2011	Phase 1
NCT01284595	Completed	Healthy	AstraZeneca	March 2011	Phase 1
NCT01151215	Terminated	Neoplasms\|Breast Neoplasms\|Breast Cancer	AstraZeneca	June 2010	Phase 2

参考文献
[1] Hickinson DM, et al. Clin Cancer Res, 2010, 16(4), 1159-1169.

参考文献

[1] Hickinson DM, et al. Clin Cancer Res, 2010, 16(4), 1159-1169.

化学信息&溶解度

分子量	473.93	分子式	C₂₃H₂₅ClFN₅O₃
CAS号	848942-61-0	SDF	Download Sapitinib (AZD8931) SDF
Smiles	CNC(=O)CN1CCC(CC1)OC2=C(C=C3C(=C2)C(=NC=N3)NC4=C(C(=CC=C4)Cl)F)OC
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1年-80°C溶于溶剂
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1个月-20°C溶于溶剂

体外溶解度
批次：

DMSO : 40 mg/mL ( (84.4 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : Insoluble

Ethanol : Insoluble

DMSO : 95 mg/mL ( (200.45 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : Insoluble

Ethanol : Insoluble

DMSO : 95 mg/mL ( (200.45 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩尔浓度计算器

体内溶解度
批次：

现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂

动物体内配方计算器

实验计算

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Sapitinib (AZD8931)

产品质控

Sapitinib (AZD8931)相关产品

相关信号通路图

细胞实验数据示例

生物活性

化学信息&溶解度

实验计算

技术支持